Prevalence and factors associated with sleep disturbance in adult patients with psoriasis.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
22
05
2021
accepted:
16
12
2021
pubmed:
13
1
2022
medline:
15
4
2022
entrez:
12
1
2022
Statut:
ppublish
Résumé
Sleep, which is crucial for restoring of physiological functions and health, is reportedly impaired in psoriasis. The role of different potential sleep confounding factors, including detailed pruritus characteristics, and the complex interplay between psychological variables (anxiety and depression), pruritus and sleep disturbance in psoriasis remain insufficiently investigated. To investigate sleep characteristics and to identify clinical, demographic and psychological factors associated with sleep disturbance in psoriasis. This cross-sectional study included 334 psoriasis patients (response rate 86%) and 126 control subjects (response rate 82%). Measures included sleep quality [Pittsburgh Sleep Quality Index (PSQI)], psoriasis severity, pruritus characteristics, including average pruritus intensity [visual analogue scale (VAS)], severity of comorbidities, anxiety and depression (Hospital Anxiety and Depression Scale - HADS) and quality of life (Dermatology Life Quality Index - DLQI, and Short Form 12 - SF12). Fifty-nine per cent of patients and 34% of control subjects (P < 0.001) suffered from sleep disturbance (PSQI > 5). Patients slept 1 h less than control subjects (median 6 vs. 7 h, P < 0.001). Patients without pruritus had less impaired sleep (global PSQI) than patients with strong (P < 0.001) and very strong pruritus (P < 0.001). Anxiety (HADS-A) and depression (HADS-D) levels were the strongest predictors of sleep impairment, followed by pruritus exacerbation at night, age, female sex, pruritus exacerbation in the morning, average pruritus intensity (VAS), diagnosed depression and gastroesophageal reflux disease, altogether explaining 32%-37% of the variance in global sleep quality. Both anxiety (HADS-A) and depression (HADS-D) were significant mediators explaining the association between pruritus intensity (VAS) and sleep impairment in 42% and 37% respectively. Sleep disturbance in patients with psoriasis is highly prevalent. Patients with psoriasis should be assessed for sleep impairment, pruritus, anxiety and depression. Reduction in pruritus should be considered as an important therapeutic goal, along with therapies aimed at reducing anxiety and depression.
Sections du résumé
BACKGROUND
BACKGROUND
Sleep, which is crucial for restoring of physiological functions and health, is reportedly impaired in psoriasis. The role of different potential sleep confounding factors, including detailed pruritus characteristics, and the complex interplay between psychological variables (anxiety and depression), pruritus and sleep disturbance in psoriasis remain insufficiently investigated.
OBJECTIVES
OBJECTIVE
To investigate sleep characteristics and to identify clinical, demographic and psychological factors associated with sleep disturbance in psoriasis.
METHODS
METHODS
This cross-sectional study included 334 psoriasis patients (response rate 86%) and 126 control subjects (response rate 82%). Measures included sleep quality [Pittsburgh Sleep Quality Index (PSQI)], psoriasis severity, pruritus characteristics, including average pruritus intensity [visual analogue scale (VAS)], severity of comorbidities, anxiety and depression (Hospital Anxiety and Depression Scale - HADS) and quality of life (Dermatology Life Quality Index - DLQI, and Short Form 12 - SF12).
RESULTS
RESULTS
Fifty-nine per cent of patients and 34% of control subjects (P < 0.001) suffered from sleep disturbance (PSQI > 5). Patients slept 1 h less than control subjects (median 6 vs. 7 h, P < 0.001). Patients without pruritus had less impaired sleep (global PSQI) than patients with strong (P < 0.001) and very strong pruritus (P < 0.001). Anxiety (HADS-A) and depression (HADS-D) levels were the strongest predictors of sleep impairment, followed by pruritus exacerbation at night, age, female sex, pruritus exacerbation in the morning, average pruritus intensity (VAS), diagnosed depression and gastroesophageal reflux disease, altogether explaining 32%-37% of the variance in global sleep quality. Both anxiety (HADS-A) and depression (HADS-D) were significant mediators explaining the association between pruritus intensity (VAS) and sleep impairment in 42% and 37% respectively.
CONCLUSIONS
CONCLUSIONS
Sleep disturbance in patients with psoriasis is highly prevalent. Patients with psoriasis should be assessed for sleep impairment, pruritus, anxiety and depression. Reduction in pruritus should be considered as an important therapeutic goal, along with therapies aimed at reducing anxiety and depression.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
688-697Subventions
Organisme : The International Institute of Dermatological Allergology
ID : I2DEAL
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.
Références
Parisi R, Symmons DP, Griffiths CE et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013; 133: 377-385.
Griffiths CEM, Jo SJ, Naldi L et al. A multidimensional assessment of the burden of psoriasis: results from a multinational dermatologist and patient survey. Br J Dermatol 2018; 179: 173-181.
Irwin MR. Why sleep is important for health: a psychoneuroimmunology perspective. Annu Rev Psychol 2015; 66: 143-172.
Krueger JM, Frank MG, Wisor JP, Roy S. Sleep function: toward elucidating an enigma. Sleep Med Rev 2016; 28: 46-54.
Taheri S, Lin L, Austin D, Young T, Mignot E. Short sleep duration is associated with reduced leptin, elevated ghrelin, and increased body mass index. PLoS Med. 2004; 1: e62.
Gangwisch JE. A review of evidence for the link between sleep duration and hypertension. Am J Hypertens 2014; 27: 1235-1242.
Henry A, Katsoulis M, Masi S et al. The relationship between sleep duration, cognition and dementia: a Mendelian randomization study. Int J Epidemiol 2019; 48: 849-860.
Zeng Y, Wu J, Yin J, Chen J, Yang S, Fang Y. Association of the combination of sleep duration and sleep quality with quality of life in type 2 diabetes patients. Qual Life Res 2018; 27: 3123-3130.
Gangwisch JE, Heymsfield SB, Boden-Albala B et al. Sleep duration as a risk factor for diabetes incidence in a large U.S. sample. Sleep 2007; 30: 1667-1673.
Yaggi HK, Araujo AB, McKinlay JB. Sleep duration as a risk factor for the development of type 2 diabetes. Diabetes Care 2006; 29: 657-661.
Gangwisch JE, Heymsfield SB, Boden-Albala B et al. Short sleep duration as a risk factor for hypertension: analyses of the first National Health and Nutrition Examination Survey. Hypertension 1979; 2006(47): 833-839.
Zhai L, Zhang H, Zhang D. Sleep duration and depression among adults: a meta-analysis of prospective studies. Depress Anxiety 2015; 32: 664-670.
Takeshita J, Grewal S, Langan SM et al. Psoriasis and comorbid diseases: Epidemiology. J Am Acad Dermatol 2017; 76: 377-390.
Chiu HY, Hsieh CF, Chiang YT et al. Concomitant sleep disorders significantly increase the risk of cardiovascular disease in patients with psoriasis. PLoS One 2016; 11: e0146462.
Gupta MA, Gupta AK, Kirkby S et al. Pruritus in psoriasis. A prospective study of some psychiatric and dermatologic correlates. Arch. Dermatol. 1988; 124: 1052-1057.
Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch. Dermatol. 2001; 137: 280-284.
Mease PJ, Menter MA. Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective. J Am Acad Dermatol 2006; 54: 685-704.
Melikoglu M. Sleep quality and its association with disease severity in psoriasis. Eurasian J Med 2017; 49: 124-127.
Jensen P, Zachariae C, Skov L, Zachariae R. Sleep disturbance in psoriasis: a case-controlled study. Br J Dermatol 2018; 179: 1376-1384.
Wong ITY, Chandran V, Li S, Gladman DD. Sleep disturbance in psoriatic disease: prevalence and associated factors. J Rheumatol 2017; 44: 1369-1374.
Kaaz K, Szepietowski JC, Matusiak L. Influence of itch and pain on sleep quality in atopic dermatitis and psoriasis. Acta Derm Venereol 2019; 99: 175-180.
Henry AL, Kyle SD, Chisholm A, Griffiths CEM, Bundy C. A cross-sectional survey of the nature and correlates of sleep disturbance in people with psoriasis. Br J Dermatol 2017; 177: 1052-1059.
Henry AL, Kyle SD, Bhandari S, Chisholm A, Griffiths CE, Bundy C. Measurement, classification and evaluation of sleep disturbance in psoriasis: a systematic review. PLoS One 2016; 11: e0157843.
Strober BE, Sobell JM, Duffin KC et al. Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial. Br J Dermatol 2012; 167: 1374-1381.
Mrowietz U, Chouela EN, Mallbris L et al. Pruritus and quality of life in moderate-to-severe plaque psoriasis: post hoc explorative analysis from the PRISTINE study. J Eur Acad Dermatol Venereol 2015; 29: 1114-1120.
Zachariae R, Zachariae CO, Lei U, Pedersen AF. Affective and sensory dimensions of pruritus severity: associations with psychological symptoms and quality of life in psoriasis patients. Acta Derm Venereol 2008; 88: 121-127.
Gupta MA, Gupta AK, Kirkby S et al. Pruritus associated with nocturnal wakenings: organic or psychogenic? J Am Acad Dermatol 1989; 21: 479-484.
Buysse DJ, Reynolds CF, 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989; 28: 193-213.
Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J Am Geriatr Soc 1968; 16: 622-626.
Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the hospital anxiety and depression scale. An updated literature review. J Psychosom Res 2002; 52: 69-77.
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361-370.
Ware J, Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996; 34: 220-233.
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216.
Hayes A. Introduction to mediation, moderation, and conditional process analysis: A regression-based approach. Guilford Publications. 2017.
Hinz A, Glaesmer H, Brähler E et al. Sleep quality in the general population: psychometric properties of the Pittsburgh Sleep Quality Index, derived from a German community sample of 9284 people. Sleep Med 2017; 30: 57-63.
Watson NF, Badr MS, Belenky G et al. Recommended amount of sleep for a healthy adult: a Joint Consensus Statement of the American Academy of Sleep Medicine and Sleep Research Society. Sleep 2015; 38: 843-844.
Smiley A, King D, Bidulescu A. The association between sleep duration and metabolic syndrome: the NHANES 2013/2014. Nutrients 2019; 11: 2582.
Spindler M, Przybyłowicz K, Hawro M et al. Sleep disturbance in adult dermatological patients: a cross-sectional study on prevalence, burden and associated factors. J Am Acad Dermatol 2021; 85: 910-922.
Hawro T, Przybyłowicz K, Spindler M et al. The characteristics and impact of pruritus in adult dermatology patients: a prospective, cross-sectional study. J Am Acad Dermatol 2021; 84: 691-700.
Luca M, Luca A, Musumeci ML, Fiorentini F, Micali G, Calandra C. Psychopathological variables and sleep quality in psoriatic patients. Int J Mol Sci 2016; 17: 1184.
Sampogna F, Chren MM, Melchi CF, Pasquini P, Tabolli S, Abeni D. Age, gender, quality of life and psychological distress in patients hospitalized with psoriasis. Br J Dermatol 2006; 154: 325-331.
Hawro M, Maurer M, Weller K et al. Lesions on the back of hands and female gender predispose to stigmatization in patients with psoriasis. J Am Acad Dermatol 2017; 76: 648-654.e642.
Stein MB, Belik SL, Jacobi F, Sareen J. Impairment associated with sleep problems in the community: relationship to physical and mental health comorbidity. Psychosom Med 2008; 70: 913-919.
Reszke R, Bialynicki-Birula R, Szepietowski JC. Itch in psoriasis: a new look at well-known subject. Acta Derm Venereol 2019; 99: 429-434.
Choi JW, Lee J, Jung SJ, Shin A, Lee YJ. Use of sedative-hypnotics and mortality: a population-based retrospective cohort study. J Clin Sleep Med 2018; 14: 1669-1677.
Krajewska-Wlodarczyk M, Owczarczyk-Saczonek A, Placek W. Sleep disorders in patients with psoriatic arthritis and psoriasis. Reumatologia 2018; 56: 301-306.
Burns A, Hofer S, Curry P, Sexton E, Doyle F. Revisiting the dimensionality of the Hospital Anxiety and Depression Scale in an international sample of patients with ischaemic heart disease. J Psychosom Res 2014; 77: 116-121.
Palacios JE, Khondoker M, Achilla E, Tylee A, Hotopf M. A single, one-off measure of depression and anxiety predicts future symptoms, higher healthcare costs, and lower quality of life in coronary heart disease patients: analysis from a multi-wave, primary care cohort study. PLoS One 2016; 11: e0158163.
Gibbons CJ, Mills RJ, Thornton EW et al. Rasch analysis of the hospital anxiety and depression scale (HADS) for use in motor neurone disease. Health Qual Life Outcomes 2011; 9: 82.
Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol 1986; 51: 1173-1182.
Ditlevsen S, Christensen U, Lynch J, Damsgaard MT, Keiding N. The mediation proportion: a structural equation approach for estimating the proportion of exposure effect on outcome explained by an intermediate variable. Epidemiology 2005; 16: 114-120.